Terry, Mark (2018年11月29日). “Can Moderna Live up to the Hype? mRNA Company Increases IPO Goal to $600 Million”. BioSpace. 2020年11月16日時点のオリジナルよりアーカイブ。2020年5月19日閲覧。 “The filings with the U.S. Securities and Exchange Commission (SEC) not only updated the proposed IPO but disclosed the size of the company's largest investors' stakes. Noubar B. Afeyan, company chairman, holds 19.5 percent, or 58,882,696 shares. Flagship Pioneering holds 18 percent of Moderna shares”
Jackson, Lisa A.; Anderson, Evan J.; Rouphael, Nadine G.; Roberts, Paul C.; Makhene, Mamodikoe; Coler, Rhea N.; McCullough, Michele P.; Chappell, James D. et al. (July 14, 2020). “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”. New England Journal of Medicine0 (20): 1920–1931. doi:10.1056/NEJMoa2022483. ISSN0028-4793. PMC7377258. PMID32663912. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377258/. "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection. All side effects were considered mild or moderate. A higher, 250-microgram dose led to more serious reactions and has been set aside."
Singh, Jerome Amir; Upshur, Ross E G (2020). “The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials”. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(20)30923-3. ISSN1473-3099.
Jackson, Lisa A.; Anderson, Evan J.; Rouphael, Nadine G.; Roberts, Paul C.; Makhene, Mamodikoe; Coler, Rhea N.; McCullough, Michele P.; Chappell, James D. et al. (July 14, 2020). “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”. New England Journal of Medicine0 (20): 1920–1931. doi:10.1056/NEJMoa2022483. ISSN0028-4793. PMC7377258. PMID32663912. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377258/. "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection. All side effects were considered mild or moderate. A higher, 250-microgram dose led to more serious reactions and has been set aside."
pubmed.ncbi.nlm.nih.gov
Jackson, Lisa A.; Anderson, Evan J.; Rouphael, Nadine G.; Roberts, Paul C.; Makhene, Mamodikoe; Coler, Rhea N.; McCullough, Michele P.; Chappell, James D. et al. (July 14, 2020). “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”. New England Journal of Medicine0 (20): 1920–1931. doi:10.1056/NEJMoa2022483. ISSN0028-4793. PMC7377258. PMID32663912. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377258/. "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection. All side effects were considered mild or moderate. A higher, 250-microgram dose led to more serious reactions and has been set aside."
Catherine Elton (2013年3月). “The NEXT Next Big Thing”. Boston Magazine. 2020年11月16日時点のオリジナルよりアーカイブ。2013年12月11日閲覧。
Terry, Mark (2018年11月29日). “Can Moderna Live up to the Hype? mRNA Company Increases IPO Goal to $600 Million”. BioSpace. 2020年11月16日時点のオリジナルよりアーカイブ。2020年5月19日閲覧。 “The filings with the U.S. Securities and Exchange Commission (SEC) not only updated the proposed IPO but disclosed the size of the company's largest investors' stakes. Noubar B. Afeyan, company chairman, holds 19.5 percent, or 58,882,696 shares. Flagship Pioneering holds 18 percent of Moderna shares”
Jackson, Lisa A.; Anderson, Evan J.; Rouphael, Nadine G.; Roberts, Paul C.; Makhene, Mamodikoe; Coler, Rhea N.; McCullough, Michele P.; Chappell, James D. et al. (July 14, 2020). “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”. New England Journal of Medicine0 (20): 1920–1931. doi:10.1056/NEJMoa2022483. ISSN0028-4793. PMC7377258. PMID32663912. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377258/. "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection. All side effects were considered mild or moderate. A higher, 250-microgram dose led to more serious reactions and has been set aside."
Singh, Jerome Amir; Upshur, Ross E G (2020). “The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials”. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(20)30923-3. ISSN1473-3099.
